title: Minimal exposure intra-arterial chemotherapy for children with retinoblastoma and 13q syndrome.
abstract: Two infants with retinoblastoma and 13q syndrome with multiorgan system anomalies were treated with targeted intra-arterial chemotherapy (IAC) using one-to-three cycles of melphalan 5 mg to avoid systemic chemotherapeutic side effects. Both patients showed good response, with tumor control and no systemic chemotherapy side effects. Of the treatment modalities currently available, IAC may represent an optimal balance between tumor extermination and adverse drug reactions in this patient population with classically reduced multiorgan reserve.
authors.affiliation: School of Medicine, New York University, New York, USA.
authors.forename: Alexander B
authors.initials: AB
authors.lastname: Dillon
authors.affiliation: Ocular Oncology Service, Wills Eye Institute, Thomas Jefferson University, Philadelphia, USA.
authors.forename: Alexzandra
authors.initials: A
authors.lastname: Douglass
authors.affiliation: Department of Neurosurgery, Thomas Jefferson University, Philadelphia, USA.
authors.forename: Pascal
authors.initials: P
authors.lastname: Jabbour
authors.affiliation: Ocular Oncology Service, Wills Eye Institute, Thomas Jefferson University, Philadelphia, USA.
authors.forename: Carol L
authors.initials: CL
authors.lastname: Shields
keywords: 13q syndrome; intra-arterial chemotherapy; retina; retinoblastoma